Piotrowsky Alban, Burkard Markus, Schmieder Hendrik, Venturelli Sascha, Renner Olga, Marongiu Luigi
Department of Nutritional Biochemistry, University of Hohenheim, 70599, Stuttgart, Germany.
Institute of Physiology, Department of Vegetative and Clinical Physiology, University Hospital Tuebingen, 72076, Tuebingen, Germany.
Heliyon. 2024 Dec 31;11(1):e41598. doi: 10.1016/j.heliyon.2024.e41598. eCollection 2025 Jan 15.
The pancreatic ductal adenocarcinoma (PDAC) is among the deadliest tumor diseases worldwide. While treatment options have generally become more diverse, little progress has been made in the treatment of PDAC and the median survival time for patients with locally advanced PDAC is between 8.7 and 13.7 months despite treatment. The aim of this review was to explore the therapeutic potential of complementing standard therapy with natural or synthetic forms of vitamins A, C, and D. The therapeutic use of vitamins A, C, and D could be a promising addition to the treatment of PDAC. For all three vitamins and their derivatives, tumor cell-specific cytotoxicity and growth inhibition against PDAC cells has been demonstrated in vitro and in preclinical animal models. While the antitumor effect of vitamin C is probably mainly due to its pro-oxidative effect in supraphysiological concentrations, vitamin A and vitamin D exert their effect by activating nuclear receptors and influencing gene transcription. In addition, there is increasing evidence that vitamin A and vitamin D influence the tumor stroma, making the tumor tissue more accessible to other therapeutic agents. Based on these promising findings, there is a high urgency to investigate vitamins A, C, and D in a clinical context as a supplement to standard therapy in PDAC. Further studies are needed to better understand the exact mechanism of action of the individual compounds and to develop the best possible treatment regimen. This could contribute to the long-awaited progress in the treatment of this highly lethal tumor entity.
胰腺导管腺癌（PDAC）是全球最致命的肿瘤疾病之一。虽然治疗选择总体上变得更加多样，但PDAC的治疗进展甚微，局部晚期PDAC患者的中位生存时间在接受治疗后仍为8.7至13.7个月。本综述的目的是探讨用天然或合成形式的维生素A、C和D补充标准疗法的治疗潜力。维生素A、C和D的治疗用途可能是PDAC治疗中一个有前景的补充。对于所有这三种维生素及其衍生物，在体外和临床前动物模型中均已证明对PDAC细胞具有肿瘤细胞特异性细胞毒性和生长抑制作用。维生素C的抗肿瘤作用可能主要归因于其在超生理浓度下的促氧化作用，而维生素A和维生素D则通过激活核受体和影响基因转录发挥作用。此外，越来越多的证据表明维生素A和维生素D会影响肿瘤基质，使肿瘤组织更容易被其他治疗药物作用。基于这些有前景的发现，迫切需要在临床环境中研究维生素A、C和D，作为PDAC标准疗法的补充。需要进一步研究以更好地理解各个化合物的确切作用机制，并制定最佳的治疗方案。这可能有助于在治疗这种高度致命的肿瘤实体方面取得期待已久的进展。
